Cerity Partners
CNTX icon

Cerity Partners’s Context Therapeutics CNTX Stock Holding History

Cerity Partners’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.4K Hold
20,000
– – ﹤0.01% 3109
2025
Q4 		$29.4K Hold
20,000
– – ﹤0.01% 2830
2025
Q3 		$19.4K Hold
20,000
– – ﹤0.01% 2727
2025
Q2 		$13.1K Buy
20,000
+10,000
+100% +$7.19K ﹤0.01% 2615
2025
Q1 		$6.12K Hold
10,000
– – ﹤0.01% 2471
2024
Q4 		$10.5K Hold
10,000
– – ﹤0.01% 2412
2024
Q3 		$19.6K Buy
+10,000
New +$22.2K ﹤0.01% 2513

Other funds holding CNTX

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Cerity Partners's CNTX Position: Q1 2026 in Review

Cerity Partners held its Context Therapeutics (CNTX) position steady in Q1 2026 at 20,000 shares worth $52.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3109.

Cerity Partners first reported a position in CNTX in Q3 2024 and has held it in 7 quarters since. 59 funds tracked by Wall St. Rank hold CNTX as of Q1 2026.

  • Cerity Partners held 20,000 shares of Context Therapeutics worth $52.4K as of Q1 2026.
  • Cerity Partners left its Context Therapeutics share count unchanged in Q1 2026.
  • Context Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3109 holding.
  • Cerity Partners first reported a position in Context Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.